lncRNA expression profiles and associated ceRNA network analyses in epicardial adipose tissue of patients with coronary artery disease

Wang, Qianchen; Wang, Zhenyu; Xu, Qian; Chen, Xuliang; Shi, Ruizheng

doi:10.1038/s41598-021-81038-5

Cited by 16 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, several studies have shown that lncRNAs can act as ceRNAs that sequester miRNAs, thus allowing for de-repression of downstream miRNA targets ( Wang et al, 2019 ; Kang et al, 2021 ). Such integration between coding and non-coding RNA forms complex ceRNA networks that when dysregulated lead to cardiac remodeling after MI( Wang et al, 2021 ). We constructed a lncRNA-miRNA-mRNA ceRNA network and found that Mirt1 exhibited an obvious network hub feature, and the highest-degree microRNA related to Mirt1 was miR-466i-5p.…”

Section: Discussionmentioning

confidence: 99%

lncRNA Mirt1: A Critical Regulatory Factor in Chronic Intermittent Hypoxia Exaggerated Post-MI Cardiac Remodeling

Xing

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Chronic intermittent hypoxia (CIH) is the main feature of obstructive sleep apnea (OSA) and is known to exaggerate cardiac remodeling after myocardial infarction (MI). However, the specific contribution of CIH to overall OSA-induced pathological complications and the transcriptomic mechanisms underlying CIH-exaggerated post-MI remodeling remains unclear. In this study, we used RNA-sequencing to construct the expression profiles of cardiac mRNAs, microRNAs, and long non-coding RNAs (lncRNA) in four groups of C57BL/6J mice (Sham, CIH, MI, MI + CIH) to evaluate how CIH regulates cardiac remodeling after MI. Compared with the other three groups, the MI + CIH group exhibited 345 lncRNAs, 35 microRNAs, and 5,220 differentially expressed mRNAs. Further analysis showed that CIH led to significant changes in Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of the differentially expressed mRNAs. Co-expression network analysis identified two core lncRNAs (Mirt1 and AC125351.1) and two core microRNAs (miR-466i-5p and miR-574-5p) during the development of CIH-exaggerated post-MI remodeling, and they were verified by quantitative real-time PCR (qRT-PCR). LncRNA-mRNA correlation analysis further showed that lncRNA Mirt1 was positively correlated with Apbb1ip and Lcp2. In addition, microRNA-mRNA correlation analysis showed that microRNA miR-466i-5p was positively correlated with Snai2, Cdc27, and Ngfr. Furthermore, combining with lncRNA-mRNA and miRNA-mRNA networks, 44 RNAs were identified in the competitive endogenous RNA (ceRNA) network. Mirt1 acts as a ceRNA to bind to miR-466i-5p to further regulate the expression levels of the target gene, thereby aggravating cardiac remodeling after MI. In conclusion, our study provides a systematic perspective on the potential functions of mRNAs, microRNAs, and lncRNAs in CIH-exaggerated post-MI cardiac remodeling. Our data suggest that lncRNA Mirt1 may be the most critical regulator of MI aggravated by CIH.

show abstract

Section: Discussionmentioning

confidence: 99%

lncRNA Mirt1: A Critical Regulatory Factor in Chronic Intermittent Hypoxia Exaggerated Post-MI Cardiac Remodeling

Xing

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Time-ordered ceRNA networks are constructed in ischemic and dilated cardiomyopathy (33). The ceRNA network controls inflammation through tanshinone IIA in atherosclerosis (34), affects metabolic and proinflammatory responses in coronary artery disease (CAD) (35), and regulates inflammation and cell proliferation in remote ischemic preconditioning of myocardial ischemia-reperfusion injury (36). NEAT1formed ceRNA participates in endothelial dysfunction by regulating inflammation in vein graft failure (37).…”

Section: Discussionmentioning

confidence: 99%

Potential of ATP5MG to Treat Metabolic Syndrome-Associated Cardiovascular Diseases

Liu

Zhou

Chen

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

IntroductionMetabolic syndrome-associated cardiovascular disease (MetS-CVD) is a cluster of metabolism-immunity highly integrated diseases. Emerging evidence hints that mitochondrial energy metabolism may be involved in MetS-CVD development. The physiopathological role of ATP5MG, a subunit of the F0 ATPase complex, has not been fully elucidated.MethodsIn this study, we selected ATP5MG to identify the immunity-mediated pathway and mine drugs targeting this pathway for treating MetS-CVD. Using big data from public databases, we dissected co-expressed RNA (coRNA), competing endogenous RNA (ceRNA), and interacting RNA (interRNA) genes for ATP5MG.ResultsIt was identified that ATP5MG may form ceRNA with COX5A through hsa-miR-142-5p and interplay with NDUFB8, SOD1, and MDH2 through RNA–RNA interaction under the immune pathway. We dug out 251 chemicals that may target this network and identified some of them as clinical drugs. We proposed five medicines for treating MetS-CVD. Interestingly, six drugs are being tested to treat COVID-19, which unexpectedly offers a new potential host-targeting antiviral strategy.ConclusionCollectively, we revealed the potential significance of the ATP5MG-centered network for developing drugs to treat MetS-CVD, which offers insights into the epigenetic regulation for metabolism-immunity highly integrated diseases.

show abstract

“…Finally, there is increasing evidence that lncRNAs are able to affect the expression of protein-coding genes by competitively binding to shared miRNAs, which then reduces the degradation of protein-coding genes. Several studies have found that lncRNA-associated competing endogenous RNA cross-talks with cardiovascular disease pathogenetic processes [ 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

Artificial Intelligence-Assisted Identification of Genetic Factors Predisposing High-Risk Individuals to Asymptomatic Heart Failure

Yang

Yeh

Tsai

et al. 2021

Cells

View full text Add to dashboard Cite

Heart failure (HF) is a global pandemic public health burden affecting one in five of the general population in their lifetime. For high-risk individuals, early detection and prediction of HF progression reduces hospitalizations, reduces mortality, improves the individual’s quality of life, and reduces associated medical costs. In using an artificial intelligence (AI)-assisted genome-wide association study of a single nucleotide polymorphism (SNP) database from 117 asymptomatic high-risk individuals, we identified a SNP signature composed of 13 SNPs. These were annotated and mapped into six protein-coding genes (GAD2, APP, RASGEF1C, MACROD2, DMD, and DOCK1), a pseudogene (PGAM1P5), and various non-coding RNA genes (LINC01968, LINC00687, LOC105372209, LOC101928047, LOC105372208, and LOC105371356). The SNP signature was found to have a good performance when predicting HF progression, namely with an accuracy rate of 0.857 and an area under the curve of 0.912. Intriguingly, analysis of the protein connectivity map revealed that DMD, RASGEF1C, MACROD2, DOCK1, and PGAM1P5 appear to form a protein interaction network in the heart. This suggests that, together, they may contribute to the pathogenesis of HF. Our findings demonstrate that a combination of AI-assisted identifications of SNP signatures and clinical parameters are able to effectively identify asymptomatic high-risk subjects that are predisposed to HF.

show abstract

lncRNA expression profiles and associated ceRNA network analyses in epicardial adipose tissue of patients with coronary artery disease

Cited by 16 publications

References 39 publications

lncRNA Mirt1: A Critical Regulatory Factor in Chronic Intermittent Hypoxia Exaggerated Post-MI Cardiac Remodeling

lncRNA Mirt1: A Critical Regulatory Factor in Chronic Intermittent Hypoxia Exaggerated Post-MI Cardiac Remodeling

Potential of ATP5MG to Treat Metabolic Syndrome-Associated Cardiovascular Diseases

Artificial Intelligence-Assisted Identification of Genetic Factors Predisposing High-Risk Individuals to Asymptomatic Heart Failure

Contact Info

Product

Resources

About